3 New Strong Buy Ratings from Top-Rated Analysts: 03/21/2025

By Mijuško Šibalić, Stock Market Writer and Stock Researcher
March 21, 2025 6:07 AM UTC
3 New Strong Buy Ratings from Top-Rated Analysts: 03/21/2025

Hot off the presses! Here are the latest Strong Buy recommendations, courtesy of our Strong Buy Stocks from Top Wall Street Analysts screener:

  • Marvell Technology Inc (NASDAQ: MRVL) enjoys 18 Strong Buy ratings — here’s the latest one 
  • Gilead Sciences Inc (NASDAQ: GILD) continues to perform well (and this trajectory could continue)
  • Learn why US Foods Holding (NYSE: USFD) earns the esteemed title of “Stock of the Week”

Gain access to dozens of alerts like this per week 👉👉 Try WallStreetZen Premium 

1. Marvell Technology Inc (NASDAQ: MRVL)

A quiet powerhouse in the semiconductor space, Marvell Technology has carved out a dominant position in data infrastructure, AI, and cloud computing. The company’s latest earnings call, although most metrics came in at or above estimates, disappointed investors, although Wall Street remains confident regarding long-term growth prospects — so MRVL stock may be available at a pretty significant discount.

Zen Rating: B (Buy)see full analysis >  

Recent Price: $70.40  — get current quote > 

Max 1-year forecast: $150.00 

Why we’re watching:

  • A whopping 23 analysts issue ratings for MRVL shares. A vast majority — 18, to be exact, have given it a Strong Buy rating, while the remaining ratings are divided between 4 Buys and 1 Hold. See the ratings
  • The average 12-month price forecast for Marvell Technology stock implies a 76.26% upside.
  • Stifel Nicolaus researcher Tore Svanberg (a top 6% rated analyst) reiterated an earlier Strong Buy rating following the company’s Q4 and FY 2025 earnings call. The analyst cut his price target from $130 to $115.
  • Svanberg said the adjustment was "entirely on lower comps." Looking ahead, custom ASIC is seeing further momentum, the analyst said, with two programs in high-volume production at two lead hyperscalers and a third hyperscaler on track for a ramp in CY 2026.
  • Many of the same sentiments were echoed by Citigroup’s Atif Malik (a top 1% rated analyst), who slashed his price target on MRVL stock from $136 to $122 while keeping a Strong Buy rating. 
  • Looking ahead, Malik told readers that Citigroup still believes Marvell Technology will take advantage of the "robust" AI investment macro to swiftly scale its application-specific integrated circuit business.  
  • Marvell Technology stock has an overall Zen Rating of B, and currently ranks in the top 7% of equities according to the 115 factors our system takes into account.
  • Looking at MRVL’s Component Grade ratings, one instantly jumps off the page — Growth. In this category, the stock ranks in the 99th percentile. (See all 7 Zen Component Grades here >)

2. Gilead Sciences Inc (NASDAQ: GILD)

Gilead Sciences operates in the dynamic world of biotech. In recent years, it has increasingly shifted its focus to oncology and cell therapy. With the market in the middle of a downturn, defensive plays have begun to receive more attention from investors — and Gilead Sciences is in a great position to benefit from the shift.

Zen Rating: A (Strong Buy)see full analysis >  

Recent Price: $112.26  — get current quote > 

Max 1-year forecast:  $140.00

Why we’re watching:

  • At present, 21 analysts offer ratings and price targets for GILD stock. The ratings are evenly split between 7 Strong Buys, 7 Buys, and 7 Holds. See the ratings 
  • Matthew Harrison of Morgan Stanley (a top 23% rated analyst) maintained a Strong Buy rating on Gilead Sciences stock on March 11 and raised his 12-month price forecast from $123 to $130.
  • Harrison said they hiked their price target on Gilead Sciences after Morgan Stanley raised its Livdelzi estimates on recently completed physician checks indicating a "strong early launch" for the oral prescription medicine.
  • GILD carries an overall Zen Rating of A — and stocks in this category have provided an average annual return of 32.52% since the early 2000s.
  • Moreover, Gilead Sciences stock actually ranks in the top 1% of the equities we track.
  • The stock’s Sentiment Component Grade rating, which measures analyst revisions, earnings surprises, short interest, and insider selling, is an A — and in this category, GILD ranks in the top 3% of the stocks our system keeps track of.
  • We’d be remiss not to mention GILD’s Value and Financials ratings — as it is in the 94th and 93rd percentile, respectively, in these categories. (See all 7 Zen Component Grades here >)

3. US Foods Holding (NYSE: USFD)

Food — whether you’re peckish or famished, gluten-free, pescatarian, or anything in between, we all need it. You might “need” to add USFD to your stock portfolio as well. Well, need might be a strong word — but once you see why our Editor-in-Chief selected US Foods Holding ahead of any other stock this week, we have little doubt that you’ll want to include it in your holdings. Not to spoil the surprise, but this defensive pick has provided quite outsized returns in the past couple of years.

Zen Rating: B (Buy)see full analysis >  

Recent Price: $65.99   — get current quote > 

Max 1-year forecast: $85.00

Why we’re watching:

  • USFD is our Stock of the Week. Our Zen Investor Editor-in-Chief, Steve Reitmeister, did a deep dive on US Foods Holding in a Monday article. We highly suggest you take a look at the article — but here are a couple of highlights.
  • USFD is in the 93.49 percentile of all stocks we analyze...but only those 95.00 and above are A.
  • Steve referred to the stock as the most conservative holding in his Zen Investor portfolio. However, on top of a top 2% reading for Safety, USFD also ranks highly in terms of Value, Momentum, Financials, and Growth.
  • Over the past 5 years, the company’s earnings have doubled — while share prices have quadrupled.
  • Wall Street seems to be on board — Mark Carden of UBS (a top 19% rated analyst) recently maintained a Strong Buy rating on the stock, while also increasing his price target from $77 to $83.
  • Barclays researcher Jeffrey Bernstein (a top 13% analyst) concurs — having doubled down on a previous Strong Buy rating while raising his 12-month price forecast for USFD from $82 to a Street-high $85.
  • As we’ve mentioned, Us Food Holding stock just barely misses the mark to qualify for an overall Zen Rating of A — but if things keep going the way they are, this “defensive” pick could soon qualify for the highest grade. (See all 7 Zen Component Grades here >)

What to Do Next?

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.